Alex Biese

For patients with cancer, Symproic may prevent constipation and improve quality of life.

The FDA has approved Vyloy for patients with HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma with CLDN18.2-positive tumors.

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in treatment decision-making for many.

For some patients with breast cancer, ctDNA may have the potential to predict disease relapse after they have undergone surgery and chemotherapy.

From Jenna Fischer announcing her breast cancer diagnosis to Martha Davis and the Motels canceling concerts after her radiation therapy, here’s what’s happening in the cancer space this week.

The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer.

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

Ninlaro, Thalomid and dexamethasone followed by Ninlarlo maintenance may improve durability of response in myeloma after stem cell transplantation relapse.

A study found that nearly all older patients with ER-positive DCIS could have avoided lymph node removal, researchers have stated.

More than 60% of patients with relapsed or refractory KMT2Ar acute leukemia responded to the menin inhibitor revumenib.

For patients with adenocarcinoma of the esophagus and esophagogastric junction, chemoradiotherapy and chemotherapy improved survival versus surgery alone.

Research has shown that among patients with advanced non-small cell lung cancer, early palliative care delivered by video is as effective as in-person care.

From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer.

Researchers are advising against the interruption of treatment with Gleevec among patients with advanced gastrointestinal stromal tumors.

An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.

The Hall of Famer has died from brain cancer at the age of 58, the NBA has announced.

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function.

From Ann Wilson’s return to Heart after chemotherapy to Ryan Reynolds visiting a fan with cancer, here’s what’s happening in the oncology space this week.

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.

Krazati’s benefits were seen regardless of baseline brain metastases, researchers have reported in findings from the KRYSTAL-12 trial.

An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant.

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in the oncology space this week.

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, researchers urged.

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence.

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta followed by response-guided chemotherapy experienced “exceptionally excellent” survival outcomes.